Week in Brief
President Donald Trump Signs Executive Order “Minimizing the Economic Burden of the Patient Protection and Affordable Care Act Pending Repeal.”
Senate Finance Committee Holds Hearing to Consider Congressman Tom Price (R-GA) for HHS Secretary. Senate Finance Committee Chairman Orrin Hatch (R-UT) and Ranking Member Ron Wyden (D-OR) Release Statements.
Powers Principals Peggy Tighe and Diane Millman will speak at the American Society of Transplant Surgeons’ 17th Annual State of the Art Winter Symposium Business Practice and Legislative Session in Miami on January 27.
Since the beginning of the New Year, there has been significant activity in the area of health care from a legislative and executive perspective, particularly focused on repeal and replace of the Affordable Care Act. The following is a summary of key developments:
Week in Brief
Donald Trump Is Sworn in as 45th President of the United States.
President Trump Issues Executive Order on the Affordable Care Act.
CMS Announces Final Rule, Medicaid Program; Use of New or Increased Pass‐Through Payments in Medicaid Managed Care Delivery Systems.
Agencies Finalize Federal Policy for the Protection of Human Subjects.
Powers Attorney Rebecca Burke wrote an article titled “What Does the Cures Act Mean for Medicare Telehealth Coverage?” discussing how the 21st Century Cures Act that was signed into law December 13, 2016, may affect Medicare’s telehealth benefit. The article appeared in the American Health Lawyers Association’s Weekly newsletter published January 13.
Powers Principal Larry Gondelman spoke at The George Washington University Graduate Certificate in Health Care Compliance Program Tuesday, offering students insight into the complexities of conducting internal investigations.
Week in Brief
115th Congress Commences and Certifies the Electoral College Vote. In 234-193 Vote, House Approves Rule Package Including a Provision Aiding ACA Repeal.
President Barack Obama Huddles House and Senate Democrats to Discuss Protecting the ACA. Vice President-Elect Mike Pence Huddles House Republicans to Discuss Repealing the ACA.
Today HRSA published long-awaited regulations specifying how the 340B ceiling price is calculated for a drug and creating standards for imposing civil monetary penalties (CMPs) on manufacturers that knowingly and intentionally overcharge covered entities.¹ The final rule is a major step forward toward holding drug manufacturers accountable for ensuring that covered entities are offered covered outpatient drugs at a price that does not exceed the 340B ceiling price. HRSA adopted several proposals from the 340B Coalition. The rule generally benefits covered entities, and should make it easier for covered entities to obtain refunds when they are overcharged.